Lv1
49 积分 2020-11-08 加入
A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors
13天前
已完结
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
1个月前
已完结
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers
1个月前
已完结
Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines
1个月前
已完结
Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial
2个月前
已完结
Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial
2个月前
已关闭
Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial
2个月前
已完结
Prognostic Factors for Early Recurrence After Resection of Pancreatic Cancer: A Systematic Review and Meta-Analysis
3个月前
已完结
Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy
3个月前
已完结
ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?
3个月前
已关闭
皖公网安备34019202002308
